List of Excipients in Branded Drug BALVERSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Products LP	BALVERSA	erdafitinib	59676-030	CELLULOSE, MICROCRYSTALLINE	2035-03-26
Janssen Products LP	BALVERSA	erdafitinib	59676-030	CROSCARMELLOSE SODIUM	2035-03-26
Janssen Products LP	BALVERSA	erdafitinib	59676-030	FERRIC OXIDE YELLOW	2035-03-26

Last updated: August 9, 2026

ecutive summary: Balversa (erdafitinib) uses a conventional immediate-release, film-coated tablet platform with a short inactive-ingredient list. The commercial opportunity is strongest in excipient supply, low-dose content-uniformity solutions, coating systems, generic formulation development, analytical comparability, and CDMO manufacturing. Erdafitinib has no biosimilar pathway because it is a small molecule, but generic entry remains constrained by Orange Book patents, formulation know-how, bioequivalence requirements, and the drug's narrow biomarker-defined market. The active-ingredient patent estate is likely more important than the excipient composition itself.

Balversa Erdafitinib Excipient Strategy and Commercial Opportunities

What excipients are used in Balversa tablets?

Balversa is supplied as 3 mg, 4 mg, and 5 mg oral film-coated tablets. The formulation is designed for once-daily administration and can be taken with or without food, according to the FDA prescribing information.[1]

The disclosed inactive ingredients fall into four functional groups:

Formulation function	Likely Balversa excipient role
Diluent and compressibility aid	Lactose monohydrate, microcrystalline cellulose
Disintegrant	Croscarmellose sodium
Lubricant	Magnesium stearate
Wetting or processing aid	Sodium lauryl sulfate
Glidant	Colloidal silicon dioxide
Film coating	Polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide and iron oxide colorants

The exact qualitative and quantitative composition should be taken from the current FDA label and DailyMed record when evaluating a development or sourcing program.[1,2]

The formulation strategy is commercially significant because Balversa contains a low dose of active pharmaceutical ingredient. At 3 mg, the drug substance represents a small fraction of tablet mass. Excipients therefore determine blend uniformity, tablet weight, hardness, disintegration, dissolution, and manufacturing yield.

Why does low-dose erdafitinib create excipient opportunities?

Low-dose tablets create greater technical sensitivity than high-load products. The principal risks are:

1. Segregation of erdafitinib from the larger-volume excipient blend.
2. Poor content uniformity at the 3 mg strength.
3. Over-lubrication caused by excessive magnesium stearate or prolonged blending.
4. Compression variability across the 3 mg, 4 mg and 5 mg strengths.
5. Dissolution changes caused by particle-size variation, coating weight, or surfactant level.

A generic or line-extension developer can reduce these risks through ordered blending, carrier-based premixes, controlled particle-size distribution, roller compaction, or direct-compression excipient systems.

The strongest excipient value proposition is not a novel inactive ingredient. It is a reproducible platform that provides:

• High-dose uniformity at low drug loading.
• Robust tablet compression across multiple strengths.
• Rapid and consistent disintegration.
• Dissolution matching against the reference product.
• Low sensitivity to changes in lubricant mixing time.
• Acceptable stability under commercial packaging conditions.

Which excipient suppliers have the best commercial opportunities?

Lactose and microcrystalline cellulose suppliers

Lactose monohydrate and microcrystalline cellulose are established tablet fillers. Suppliers can compete through:

• Narrow particle-size distributions.
• Low-moisture grades.
• Improved flow and compactability.
• Co-processed excipients.
• Documentation supporting elemental impurities, nitrosamines, residual solvents and microbial control.

For erdafitinib, a co-processed filler-disintegrant or high-functionality cellulose system could simplify manufacturing. The commercial constraint is that a generic applicant must demonstrate equivalent performance, not merely superior manufacturability.

Superdisintegrant suppliers

Croscarmellose sodium is central to immediate-release performance. Commercial opportunities include grades with controlled swelling, rapid water uptake and low variability between lots.

A developer may also evaluate crospovidone or sodium starch glycolate as alternatives. The substitution is technically feasible, but it can alter dissolution, tablet friability, compactability and the required formulation space for bioequivalence.

Lubricant and glidant suppliers

Magnesium stearate remains the likely primary lubricant. Excipient suppliers can differentiate through:

• Controlled specific surface area.
• Reduced hydrophobicity.
• Consistent fatty-acid composition.
• Better performance under short blending cycles.
• Lower impact on dissolution.

Colloidal silicon dioxide can improve flow for a low-dose blend. Excessive glidant, however, can alter powder segregation and tablet mechanical properties. The formulation target is controlled flow without creating density differences between the active and excipient fractions.

Film-coating suppliers

The color-coded tablet strengths create a practical opportunity for coating manufacturers and contract development organizations. A reliable coating system must provide:

• Consistent color across three strengths.
• Low coating weight variability.
• Adequate moisture protection.
• Resistance to chipping and abrasion.
• Fast processing without excessive thermal exposure.

Iron oxide colorants can create batch-to-batch shade variation and require careful dispersion control. A coating supplier offering prequalified, color-matched systems could reduce development time for generic and regional manufacturers.

What formulation patents protect Balversa?

Balversa's most important patent barriers are expected to involve erdafitinib's active compound, solid forms, pharmaceutical compositions, manufacturing processes and therapeutic uses. The commercial distinction is important:

• Composition-of-matter patents generally create the strongest exclusionary position.
• Solid-form patents can restrict particular crystalline or polymorphic forms.
• Formulation patents may protect specific tablet compositions, excipient ratios or release characteristics.
• Method-of-use patents can cover treatment of FGFR-altered urothelial carcinoma.
• Process patents can complicate non-infringing manufacture or impurity control.

The public patent estate for erdafitinib includes composition and related pharmaceutical patent families with expected terms extending from the early 2030s into the mid-2030s, depending on the patent, patent-term adjustment and claim scope.[3] The controlling analysis requires review of the current FDA Orange Book listings, patent certificates and prosecution records rather than reliance on a single expiration date.[3]

A generic formulation that avoids a specific excipient combination may still infringe a compound or method-of-use patent. Excipient substitution therefore does not by itself create freedom to operate.

When does Balversa lose exclusivity?

FDA granted accelerated approval to Balversa in April 2019 for previously treated locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 alterations.[4] The FDA later converted the indication to regular approval based on confirmatory clinical data from the THOR study.[5]

Exclusivity or barrier	Commercial effect
Five-year new chemical entity exclusivity	Delayed ANDA submission during the initial period, subject to statutory exceptions
Patent protection	May block approval or launch after regulatory exclusivity ends
Method-of-use protection	Can require carve-outs, skinny labeling or litigation
Formulation and solid-form protection	Can limit alternative product designs
Biomarker-defined indication	Reduces the addressable generic market but supports premium pricing
No biologic exclusivity	Biosimilar rules do not apply

The NCE exclusivity period has ended. The remaining commercial protection is therefore driven primarily by patents, litigation outcomes, regulatory review and the economics of treating a molecularly selected population.

What is the Orange Book status of Balversa?

Balversa is an FDA-approved small-molecule prescription drug and is subject to the Abbreviated New Drug Application pathway. Its Orange Book status is relevant to any applicant considering an erdafitinib generic.[3]

A prospective ANDA applicant must evaluate:

• Listed patents covering the active ingredient.
• Formulation or composition patents.
• Use codes attached to method-of-use patents.
• Patent-term expiration and adjustment.
• Pediatric exclusivity, if listed.
• Whether a Paragraph IV certification is commercially justified.

The FDA Orange Book does not itself determine infringement. It identifies patents and use codes submitted by the NDA holder. The applicant must compare its proposed product, labeling and manufacturing process with the issued claims.

Which companies are challenging Balversa exclusivity?

Public generic competition should be assessed through FDA ANDA records, Paragraph IV notices and federal patent litigation databases. A definitive competitor list requires current docket and Orange Book review. The likely competitive field includes large generic companies with oncology manufacturing capabilities, regional pharmaceutical companies and specialty generics developers.

The most credible entrants will have:

• Existing oral oncology manufacturing capacity.
• Experience with low-dose potent compounds.
• Strong analytical development capabilities.
• Sufficient resources for Paragraph IV litigation.
• Distribution reach into oncology practices and specialty pharmacies.

Because erdafitinib targets FGFR alterations, the product is less attractive to commodity generic manufacturers than a high-volume primary-care drug.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV strategy could challenge invalidity, non-infringement or unenforceability of listed patents. The principal arguments could involve:

• Obviousness of the erdafitinib compound or formulation.
• Lack of written description or enablement.
• Failure to meet patentable novelty requirements.
• Non-infringement based on a different solid form or excipient composition.
• Labeling that omits patented treatment methods.

The most relevant generic launch scenarios are:

Scenario	Likely outcome
No Paragraph IV challenge	Entry waits for patent expiry or negotiated license
Paragraph IV with settlement	Launch occurs on an agreed date, potentially before expiry
Successful invalidity challenge	Early launch becomes possible
Successful non-infringement defense	Alternative formulation may enter
Failed challenge	Generic launch is delayed until the relevant patent expires

No settlement should be assumed without a public court filing, SEC disclosure or other authoritative record. Settlement agreements can include launch dates, licenses, supply restrictions, authorized-generic provisions and limits on competing formulations.

How strong is the Balversa patent estate?

The estate is commercially stronger when compound claims, solid-form claims and method-of-use claims overlap. A generic developer that avoids one layer may still face another.

Patent layer	Relative commercial strength
Composition of matter	Highest, because excipient substitution does not avoid the claim
Solid form	High if the reference product uses a claimed form and alternatives are difficult to develop
Pharmaceutical composition	Moderate to high, depending on claim breadth
Method of use	Moderate, subject to label design and use-code scope
Manufacturing process	Variable, depending on process necessity
Excipient-specific claim	Narrower and more vulnerable to design-around

The patent estate is less powerful if non-infringing crystalline forms, alternative salt forms or different tablet compositions provide equivalent exposure and dissolution. It is stronger if the active compound has limited solid-state options or if the reference product's manufacturing process is difficult to replicate.

What manufacturing and intellectual-property barriers affect erdafitinib generics?

Erdafitinib is a potent targeted oncology compound. Manufacturing barriers can include occupational exposure controls, containment, cleaning validation, cross-contamination prevention, and control of genotoxic or mutagenic impurities.

The commercial value of a CDMO may extend beyond tablet compression. Opportunities include:

• Contained dispensing and blending.
• Low-dose premix manufacturing.
• Potent-compound granulation.
• Film coating in contained equipment.
• Stability-indicating analytical methods.
• Reference-product reverse engineering.
• Extractables and leachables assessment.
• Process validation at commercial scale.

A supplier that can provide both excipient engineering and contained manufacturing is better positioned than an ingredient-only vendor.

How does Balversa compare with competing FGFR drugs?

Erdafitinib competes with other targeted oncology products, but its excipient opportunity differs from drugs with injectable or biologic formats.

Product category	Dosage form	Excipient opportunity
Balversa, erdafitinib	Low-dose oral film-coated tablet	Content uniformity, dissolution and coating
FGFR inhibitors in development	Oral tablets or capsules	Solid-state and bioavailability optimization
Monoclonal antibodies	Sterile injectable biologics	Stabilizers, surfactants and container systems
Conventional urothelial cancer drugs	Oral or injectable	Larger-volume generic competition

Balversa has no biosimilar risk. Competition will come from generic erdafitinib, alternative FGFR inhibitors, chemotherapy, immune checkpoint inhibitors and combination regimens.

What are the commercial opportunities in Balversa excipients?

The most actionable opportunities are:

1. Supply of low-moisture lactose and high-functionality microcrystalline cellulose.
2. Superdisintegrants optimized for low-dose immediate-release tablets.
3. Magnesium stearate grades with low dissolution impact.
4. Color-matched film-coating systems for 3 mg, 4 mg and 5 mg tablets.
5. Co-processed excipients that improve blend uniformity.
6. CDMO services for potent oral oncology products.
7. Analytical packages for dissolution, content uniformity and impurity control.
8. Packaging systems that limit moisture and light exposure.
9. Licensing of non-infringing solid forms or manufacturing processes.
10. Regional generic development after patent and regulatory review.

Revenue exposure depends on the size of the erdafitinib market, the number of generic entrants and whether generic substitution is permitted in each jurisdiction. Excipient suppliers generally capture a small per-tablet value but can obtain durable revenue through multi-year supply agreements, dual-source qualification and broader use across oncology portfolios.

What regulatory status governs Balversa and generic development?

The reference product was approved through the FDA NDA pathway, initially under accelerated approval and later supported by confirmatory clinical evidence.[4,5] A generic developer would normally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence.

Key regulatory workstreams include:

• Same active ingredient and dosage form.
• Equivalent strength and route of administration.
• Comparative dissolution.
• Content uniformity.
• Stability under ICH conditions.
• Impurity and degradation-product control.
• Labeling that addresses protected uses.
• Manufacturing controls for a potent compound.

Excipient changes are permitted within the ANDA framework if the resulting product meets applicable equivalence and quality requirements. A meaningful change in formulation, release profile or absorption could trigger additional FDA scrutiny.

Key takeaways

• Balversa is a low-dose, immediate-release, film-coated erdafitinib tablet.
• Its excipient platform relies on conventional fillers, a superdisintegrant, lubricant, glidant and protective coating.
• The strongest near-term opportunities are low-dose blend uniformity, coating systems, analytical services and contained CDMO manufacturing.
• Erdafitinib has no biosimilar pathway because it is a small molecule.
• Generic entry is governed mainly by active-ingredient, solid-form, formulation and method-of-use patents.
• NCE exclusivity has ended, but patent protection and litigation can continue to delay generic launch.
• Excipient substitution may support design-around efforts but does not avoid composition-of-matter or use patents.
• The biomarker-defined market limits total volume but can support specialty-pharmacy and oncology-focused commercial strategies.

FAQs about Balversa excipient and generic opportunities

Does Balversa contain lactose?

The FDA labeling identifies lactose monohydrate among the tablet excipients. Companies developing a lactose-free alternative would need to demonstrate equivalent manufacturability, dissolution, stability and bioequivalence.[1]

Can a generic company use different excipients from Balversa?

Yes. An ANDA product can use different inactive ingredients if it satisfies FDA quality and equivalence requirements. The change must also avoid infringement of any applicable formulation or composition claims.

Is erdafitinib a biologic or a small molecule?

Erdafitinib is a small-molecule FGFR inhibitor. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Does Balversa require a specialized drug-delivery system?

No specialized delivery device is required. The commercial formulation is an oral film-coated tablet. The technical challenge is low-dose solid-dose manufacturing rather than device engineering.

Which excipient is most important for erdafitinib tablet performance?

The highest-risk variables are usually the filler system, croscarmellose sodium disintegration performance, magnesium stearate lubrication and the blend process. Their combined effect determines content uniformity, tablet strength and dissolution.

References

1. U.S. Food and Drug Administration. (2024). Balversa (erdafitinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. National Library of Medicine. (2024). DailyMed: Balversa, erdafitinib tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2019, April 12). FDA approves erdafitinib for metastatic urothelial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/

5. U.S. Food and Drug Administration. (2024). FDA grants regular approval to erdafitinib for metastatic urothelial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/